Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2014-04-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2014.895323PMID 24597540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic targeting of platelet-derived growth factor receptors in solid tumors

  2014cited by this paper
• A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

  2014cited by this paper
• A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.

  2013cited by this paper
• Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors

  2013cited by this paper
• A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer

  2013cited by this paper
• Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

  2013influential reference
• A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

  2013cited by this paper
• Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

  2013cited by this paper
• A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer

  2013cited by this paper
• Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer.

  2013cited by this paper
• Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts

  2013influential reference
• Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

  2012cited by this paper
• An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

  2012cited by this paper
• Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

  2012cited by this paper
• Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

  2012cited by this paper
• Contrasting effects of sunitinib within in vivo models of metastasis

  2012cited by this paper
• Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression.

  2012cited by this paper
• Phase II open-label study of sunitinib in patients with advanced breast cancer

  2012cited by this paper
• Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors

  2012cited by this paper
• Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

  2012cited by this paper
• Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

  2012cited by this paper
• RETRACTED ARTICLE: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways

  2011cited by this paper
• Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

  2011cited by this paper
• Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases.

  2011cited by this paper
• The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness.

  2010cited by this paper
• Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.

  2010cited by this paper
• Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis

  2010cited by this paper
• Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.

  2010cited by this paper
• A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.

  2010cited by this paper
• Pazopanib: therapeutic developments

  2009cited by this paper
• An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

  2009cited by this paper
• PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment.

  2009cited by this paper
• Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.

  2009cited by this paper
• Phase I Trial of Pazopanib in Patients with Advanced Cancer

  2009cited by this paper
• Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

  2009cited by this paper
• Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.

  2008cited by this paper
• Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2008cited by this paper
• Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting

  2008cited by this paper
• Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

  2008cited by this paper
• PDGF-BB is a Novel Prognostic Factor in Colorectal Cancer

  2008cited by this paper
• Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

  2008cited by this paper
• Role of platelet-derived growth factors in physiology and medicine.

  2008cited by this paper
• Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.

  2008cited by this paper
• Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of notch-1 and nuclear factor-κB signaling

  2007cited by this paper
• Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

  2007cited by this paper
• Expression of endothelial PDGF receptors alpha and beta in breast cancer: up-regulation of endothelial PDGF receptor beta.

  2007cited by this paper
• Expression of endothelial PDGF receptors α and β in breast cancer: Up-regulation of endothelial PDGF receptor β

  2007cited by this paper
• Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling.

  2007cited by this paper
• Detection of gene amplification and deletion in high-grade gliomas using a genome DNA microarray (GenoSensor Array 300)

  2006cited by this paper
• Autocrine PDGFR signaling promotes mammary cancer metastasis.

  2006cited by this paper
• Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.

  2006cited by this paper
• KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.

  2005cited by this paper
• Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression

  2005cited by this paper
• Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.

  2005influential reference
• PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival

  2005cited by this paper
• Stromal fibroblasts in cancer initiation and progression

  2004cited by this paper
• Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer

  2004cited by this paper
• Juxtamembrane autoinhibition in receptor tyrosine kinases

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations?

  2004cited by this paper
• PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.

  2004cited by this paper
• PDGF signaling in cells and mice.

  2004cited by this paper
• Angiogenesis inhibitors in clinical development; where are we now and where are we going?

  2004influential reference
• Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review).

  2003cited by this paper
• Promises and pitfalls of anti-angiogenic therapy in clinical trials.

  2003cited by this paper
• Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.

  2003cited by this paper
• A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

  2003cited by this paper
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

  2003influential reference
• Phospholipase C-γ1 in tumor progression

  2003cited by this paper
• Platelet-derived growth factor signaling and human cancer.

  2003cited by this paper
• Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.

  2003cited by this paper
• Phospholipase C-gamma1 in tumor progression.

  2003influential reference
• Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors.

  2003cited by this paper
• Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors

  2002cited by this paper
• Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

  2002cited by this paper
• Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.

  2002cited by this paper
• Platelet-derived growth factor receptors: a therapeutic target in solid tumors.

  2001cited by this paper
• Technical Advance Degenerate Oligonucleotide Primed-Polymerase Chain Reaction-Based Array Comparative Genomic Hybridization for Extensive Amplicon Profiling of Breast Cancers A New Approach for the Molecular Analysis of Paraffin-Embedded Cancer Tissue

  2001cited by this paper
• The complexities of breast cancer desmoplasia

  2001cited by this paper
• SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

  2000cited by this paper
• Amplification of the Platelet‐Derived Growth Factor Receptor‐A (PDGFRA) Gene Occurs in Oligodendrogliomas with Grade IV Anaplastic Features

  2000cited by this paper
• Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase.

  1999cited by this paper
• PDGF‐BB increases endothelial migration and cord movements during angiogenesis in vitro

  1997cited by this paper
• Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.

  1994cited by this paper
• Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas.

  1991cited by this paper
• Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines.

  1991cited by this paper
• TUMORIGENESIS AND NEOPLASTIC PROGRESSION Pazopanib Inhibits the Activation of PDGFR b -Expressing Astrocytes in the Brain Metastatic Microenvironment of Breast Cancer Cells

  year unknowncited by this paper

• Distinctive features of cancer-associated fibroblasts expressing CD105, a novel biomarker for bone metastasis, in early-stage invasive ductal breast cancer.

  2026cites this paper
• Platelet activation in breast cancer: mechanisms and therapeutic opportunities – a narrative review

  2025cites this paper
• Knockout of histone deacetylase 8 gene in breast cancer cells may alter the expression pattern of the signaling molecules.

  2024cites this paper
• Functional and clinical roles of stromal PDGF receptors in tumor biology

  2024cites this paper
• Diverse roles of tumor-stromal PDGFB-to-PDGFRβ signaling in breast cancer growth and metastasis.

  2022cites this paper
• Characterization of prodigiosin pigment by Serratia marcescens and the evaluation of its bioactivities.

  2022cites this paper
• Risk of Thrombocytopenia With Platelet‐Derived Growth Factor Receptor Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta‐Analysis of Phase 2/3 Randomized, Controlled Trials

  2021cites this paper
• CircRNA_000543 knockdown sensitizes nasopharyngeal carcinoma to irradiation by targeting miR-9/platelet-derived growth factor receptor B axis.

  2019cites this paper
• Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.

  2019cites this paper
• The role of PDGF-B/PDGFR-BETA axis in the normal development and carcinogenesis of the breast.

  2018cites this paper
• Hematopoietic Stem Cell-derived Adipocytes Promote Tumor Growth and Cancer Cell Migration

  2017cites this paper
• The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy

  2017cites this paper
• Expression and activation of platelet-derived growth factor β receptor, mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) in canine mammary tumours.

  2017cites this paper
• Synthesis and evaluation of radioiodinated 1-{2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinolin-8-yl}piperidin-4-amine derivatives for platelet-derived growth factor receptor β (PDGFRβ) imaging.

  2017cites this paper
• miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.

  2016cites this paper
• Role of NRP-1 in VEGF-VEGFR2-Independent Tumorigenesis

  2016cites this paper
• The Roles of the Bone Marrow Microenvironment in Controlling Tumor Dormancy

  2015cites this paper
• MEK inhibitor effective against proliferation in breast cancer cell

  2014cites this paper